Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS · Delayed Price · Currency is USD
31.12
0.00 (0.00%)
Jan 27, 2026, 9:30 AM EST
TKPHF Revenue
Takeda Pharmaceutical Company had revenue of 1.19T JPY in the quarter ending December 31, 2025. This brings the company's revenue in the last twelve months to 4.52T, down -5.56% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.52T JPY
Revenue Growth
-5.56%
P/S Ratio
1.78
Revenue / Employee
95.20M JPY
Employees
47,455
Market Cap
53.22B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.68B | 8.65% |
| Mar 31, 2013 | 1.56T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
| Growth Stalk Holdings | 583.34K |
Takeda Pharmaceutical Company News
- 7 days ago - Takeda Announces US Availability Of GAMMAGARD LIQUID ERC For Primary Immunodeficiency Treatment - Nasdaq
- 7 days ago - Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Business Wire
- 8 days ago - Independence Bank of Kentucky Buys 201 Shares of Takeda Pharmaceutical Co Ltd (TAK) - GuruFocus
- 16 days ago - Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 24 days ago - Takeda Pharmaceutical, Protagonist Therapeutics Announces Submission Of NDA For Rusfertide - Nasdaq
- 24 days ago - Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Business Wire
- 6 weeks ago - Takeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug - Benzinga